ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

BAYN Bayer AG

28.77
0.185 (0.65%)
20 May 2024 - Closed
Realtime Data
Share Name Share Symbol Market Type
Bayer AG TG:BAYN Tradegate Ordinary Share
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.185 0.65% 28.77 28.63 28.825 28.945 28.54 28.605 59,387 22:50:04

Bayer Wins Fourth Roundup Weedkiller Trial in US

20/06/2022 7:15am

Dow Jones News


Bayer (TG:BAYN)
Historical Stock Chart


From May 2022 to May 2024

Click Here for more Bayer Charts.

By Ed Frankl

 

Bayer AG won a fourth case in the U.S. over claims that its Roundup weedkiller causes cancer, the company said late Friday.

A jury in Jackson County, Ore., found that the Roundup weedkiller didn't cause a man's cancer, according to the German pharmaceutical and agro-chemicals company.

It is the fourth case in a row that Bayer has won in less than a year, with the company dealing with a wave of claims since it took over Monsanto Co., the product's original owner, in 2018.

"The jury's conclusions are consistent with the assessments of expert regulators worldwide as well as the overwhelming evidence from four decades of scientific studies concluding that Roundup can be used safely and is not carcinogenic," Bayer said in a statement.

Separately, however, a U.S. federal appeals court on Friday ordered the Environmental Protection Agency to review its assessment that glyphosate, the active ingredient in Roundup, isn't harmful.

In a 3-0 decision, the Ninth Circuit Court of Appeals said the EPA hadn't adequately considered whether glyphosate causes cancer.

The previous EPA assessment is considered one of Bayer's arguments before the U.S. Supreme Court, which is expected to decide whether to review the company's award of $25 million in damages to Edwin Hardeman, who said his cancer was caused by the weedkiller.

 

Herbert Rude contributed to this article.

 

Write to Ed Frankl at edward.frankl@dowjones.com

 

(END) Dow Jones Newswires

June 20, 2022 02:00 ET (06:00 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

1 Year Bayer Chart

1 Year Bayer Chart

1 Month Bayer Chart

1 Month Bayer Chart

Your Recent History

Delayed Upgrade Clock